Janux Therapeutics Inc

JANX

Equity

ISIN null / Valor 111742522

NASDAQ (2026-03-05)

USD 13.97-2.65%

Janux Therapeutics Inc
UMushroom community rating:

3.48 43 votes No rating yet

NegativeNeutralPositive

About company

Janux Therapeutics Inc., founded in 2017, is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company leverages its proprietary technology to create next-generation T cell engagers designed to target and eliminate cancer cells while minimizing damage to healthy tissues. Janux successfully completed its initial public offering (IPO) in June 2021 and advanced its first therapeutic program to clinical trials in the latter half of 2022. The company's approach emphasizes a collaborative and data-driven culture to foster scientific innovation and accelerate the development of its therapeutic pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-55.7%1Y

-14.5%3Y

%5Y

Performance

97.6%1Y

110%3Y

102%5Y

Volatility

850 M

Market cap (USD)

1,048,318

Daily traded volume (Shares)

53.71 / 52.27

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.48

43 votes

Performance:

3.44

Innovation:

3.67

Society:

3.53

Nature:

3.31

Thomas Chamier

United Kingdom, 03 Mar 2026

Way too Volatile

Thomas Yarwood

United Kingdom, 28 Feb 2026

Industry to watch

Thomas Yarwood

United Kingdom, 27 Feb 2026

Growth potential

EQUITIES OF THE SAME SECTOR

Ste Virbac SA

Ste Virbac SA Valor: 524407

Annual Return

-50%0%+50%

Risk level

110

-0.86%EUR 346.50

Legend Biotech Corporation

Legend Biotech Corporation Valor: 54834759

Annual Return

-50%0%+50%

Risk level

110

-0.56%USD 17.75

H. Lundbeck A/S

H. Lundbeck A/S Valor: 119252587

Annual Return

-50%0%+50%

Risk level

110

-0.42%DKK 38.36

COSMO Pharmaceuticals N.V.

COSMO Pharmaceuticals N.V. Valor: 32590356

Annual Return

-50%0%+50%

Risk level

110

-0.73%CHF 108.60

Basilea Pharmaceutica Ltd, Allschwil

Basilea Pharmaceutica Ltd, Allschwil Valor: 1143244

Annual Return

-50%0%+50%

Risk level

110

-2.42%CHF 52.50

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc Valor: 30132056

Annual Return

-50%0%+50%

Risk level

110

1.46%USD 20.15

L'Oreal S.A.

L'Oreal S.A. Valor: 502805

Annual Return

-50%0%+50%

Risk level

110

-0.76%EUR 371.45

Sartorius Stedim Biotech

Sartorius Stedim Biotech Valor: 32518471

Annual Return

-50%0%+50%

Risk level

110

-2.63%EUR 170.15

DocMorris Ltd

DocMorris Ltd Valor: 4261528

Annual Return

-50%0%+50%

Risk level

110

-1.05%CHF 4.90

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc Valor: 30877188

Annual Return

-50%0%+50%

Risk level

110

-5.40%USD 75.16

Logos provided by Clearbit

Janux Therapeutics Inc

JANX

ISIN null / Valor 111742522

Janux Therapeutics Inc UMushroom community rating:

Thomas Chamier

Thomas Yarwood

Thomas Yarwood

Janux Therapeutics Inc
UMushroom community rating: